排序方式: 共有46条查询结果,搜索用时 15 毫秒
41.
目的:探讨护理干预对肺结核并咯血疗效的影响。方法:将136例肺结核并咯血患者随机分为两组。对照组给予常规治疗,实验组除给予常规药物治疗外,实施护理干预。结果:实验组咯血持续时间(3.6±O.5)d,对照组为(5.1±O.9)d,两组比较差异有统计学意义(t=5.83,P〈O.01)。实验组反复咯血1例,对照组5例,实验组反复咯血频次较对照组有明显减少(t=3.88,P〈0.05)。结论:护理干预可减少肺结核咯血的频次、缩短病程、提高治愈率、降低复发率,提高生活质量。 相似文献
42.
目的:观察吉非替尼(Iressa)单药治疗非小细胞肺癌(NSCLC)患者的近远期疗效及毒副反应.方法:48例均经病理组织学确诊的NSCLC患者,口服吉非替尼单药250 mg,1次/d,2个月后评价疗效及评价后4周疗效确认,停用吉非替尼的标准为疾病进展或不良反应不能耐受.结果:48例患者均可评价疗效,CR 4例,PR 16例,总有效率(RR)为41.6%.SD 16例,疾病控制率(DCR)为75.0%,PD 12例,性别、病理类型、吸烟史和年龄等因素都与近期有效率(RR)相关.有效患者的中位缓解时间为12个月(95%CI为5.6~16.6个月),中位生存期为12.5个月(95%CI为8.6~14.2个月),中位肿瘤进展时间为8.4个月(95%CI为4.1~10.2个月),1年生存率为42.6%.生活质量明显改善.与药物相关的不良反应依次为皮疹、腹泻、恶心、关节痛和肝功能异常.结论:吉非替尼治疗疗效明确.毒副反应较轻,耐受性较好,可以明显改善患者生存质量,作为NSCLC的治疗药物值得推广. 相似文献
43.
康泉控制肿瘤患者化疗引起的胃肠道反应 总被引:2,自引:0,他引:2
目的 观察康泉 (化学名盐酸格拉司琼 )控制肿瘤患者化疗引起的胃肠道反应的疗效。方法 10 0例随机分为两组 ,6 0例采用康泉治疗 ,40例采用胃复安加吗丁啉治疗 (对照组 ) ,并对两组的有效率进行比较。结果 康泉组控制恶心有效率为 71.7% ,对照组为 42 .5 % ,两组比较有明显差异 (p<0 .0 1) ;康泉组控制化疗所致呕吐有效率为 80 .0 % ,对照组为45 .0 % ,两组比较有明显差异 (p<0 .0 1)。结论 康泉能有效控制化疗引起的胃肠道反应。 相似文献
44.
心肌细胞条件培养液对S180细胞生长抑制作用体外实验研究 总被引:1,自引:1,他引:0
目的:通过研究心肌微环境因素对S180细胞的影响,探讨心肌内转移瘤罕见的机制.方法:原代培养新生Wistar大鼠心肌细胞,MTT法分析心肌细胞条件性上清液(CMCM)对S180细胞的体外抑制作用.以顺铂作为CMCM的阳性对照,以正常细胞鼠肾小球系膜细胞为阴性对照.采用胰酶消化法,热灭活法初步探讨心肌细胞培养液的理化性质.结果:S180细胞与CMCM共同培养后,细胞存活率明显下降,与DMEM相比差异均具有显著性(P<0.05),而对正常细胞存活率无明显影响(P>0.05).DDP对S180细胞和正常细胞均具有显著性抑制作用(P<0.05).心肌细胞培养液经胰酶消化后活性仍然存在,而经热灭活后活性消失.结论:新生大鼠心肌细胞上清液可选择性的抑制S180细胞的增殖;这种抑制作用与化疗药物顺铂作用机制不同.心肌微环境中可能存在某种抑瘤物质, 是心肌转移瘤罕见性的主要机制. 相似文献
45.
Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer 下载免费PDF全文
Objective: To explore the effect and mechanism of ginsenoside Rg3 (Shenyi Capsule, 参一胶囊) on the postoperative life span of patients with non-small cell lung cancer (NSCLC). Methods: The prospective, randomized, controlled method was adopted. One hundred and thirty- three patients with NSCLC were randomly assigned to 3 groups: Shenyi Capsule group (43 cases), combined therapy group (Shenyi Capsule plus chemotherapy, 46 cases), and chemotherapy group (44 cases). The survival rates, immune function and the correlation between vascular endothelial growth factor (VEGF) expression and clinical effect were analyzed in the three groups. Results: (1) The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% (33/43), 82.6% (38/46), and 79.5% (35/44), respectively; the 2-year survival rate was 67.4% (29/43), 71.7% (33/46), and 70.5% (31/44), respectively; and the 3-year survival rate was 46.5% (20/43), 54.3% (25/46), and 47.7% (21/44), respectively. There was no significant difference among the 3 groups (P〉0.05). (2) NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group. (3) In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression (37.0% vs 64.7%, χ^2=17.9, P〈0.01), but no significant statistical difference was shown in the other two groups (53.6% vs 55.6%, P〉0.05; 44.4% vs 50.0%, P〉0.05). Conclusion: Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis. 相似文献
46.